Curated News
By: NewsRamp Editorial Staff
April 22, 2025
Calidi Biotherapeutics to Host Investor Webinar Featuring New CMO and Oncolytic Virus Therapies
TLDR
- Calidi Biotherapeutics (NYSE American: CLDI) to showcase stem cell-based delivery platforms for oncolytic virus therapies, gaining edge in cancer treatment.
- Calidi's technology deploys allogeneic stem cells carrying oncolytic viruses to boost efficacy and safety in cancer treatment.
- Calidi's innovative approach empowers the immune system to fight cancer, offering hope for better treatment outcomes and enhanced patient safety.
- Calidi Biotherapeutics introduces new Chief Medical Officer and stem cell-based therapies for various cancers, revolutionizing oncology with cutting-edge solutions.
Impact - Why it Matters
This news matters as it highlights the advancements in cancer treatment technology by Calidi Biotherapeutics, offering potential breakthroughs for various oncology indications. The live webinar provides a unique opportunity for investors and the public to learn about the company's innovative stem cell-based platforms and the progress of its clinical stage products.
Summary
Calidi Biotherapeutics (NYSE American: CLDI) will host a live investor webinar featuring its new Chief Medical Officer, Dr. Guy Travis Clifton. The event will showcase Calidi’s stem cell-based delivery platforms for oncolytic virus therapies, including FDA-cleared products like CLD-201 for solid tumors. Updates on programs like CLD-400 for metastatic and lung cancer and CLD-101 for high-grade gliomas will also be provided, followed by a live Q&A session.
Source Statement
This curated news summary relied on this press release disributed by InvestorBrandNetwork (IBN). Read the source press release here, Calidi Biotherapeutics to Host Investor Webinar Featuring New CMO and Oncolytic Virus Therapies
